Xencor: Plamotamab NHL Data Leads To RA Program Advancement [Seeking Alpha]
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross [Yahoo! Finance]
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14% [Yahoo! Finance]
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $34.00 price target on the stock, up previously from $32.00.
Xencor, Inc. (NASDAQ: XNCR) had its price target raised by analysts at JPMorgan Chase & Co. from $27.00 to $28.00. They now have an "overweight" rating on the stock.